Thymoglobulin Capping Defects Cited In Aventis Pasteur Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA cites Genzyme’s Thymoglobulin contract manufacturer Aventis Pasteur for failures related to its quality control unit. Warning letter also points to quality control deficiencies involving haemophilius b conjugate vaccine and rabies vaccine.
You may also be interested in...
Genzyme Proposes To "Disentangle" Schering From Campath Marketing Deal
The proposal is an effort to win FTC approval for Genzyme's $1 bil. bid for Ilex. Genzyme expects to issue 22 mil. shares as part of the deal, but the dilution may be offset by stronger than previously expected performance of Renagel, Fabrazyme and Cerezyme.
Bristol To Name New R&D Head Shortly
Senior VP-Global Clinical & Pharmaceutical Development Elliott Sigal is acting president of Bristol-Myers Squibb’s research institute following the death of James Palmer.
Aranesp Performance Strong Heading Into "Transition" Time, Amgen Says
The company is talking with oncologists about Aranesp ahead of a switch in Medicare reimbursement in January 2005. U.S. sales for the red blood cell product were up 32% in the third quarter.